Cellectar BioSciences Inc. has released a corporate presentation outlining its progress in the development of phospholipid drug conjugates (PDCs) for oncology. The company's PDC platform enables the delivery of various therapeutic modalities, including radioisotopes, to target both solid and hematologic tumors. Key updates include the initiation of a Phase 1b study of CLR 125 for triple negative breast cancer, and the completion of an Investigational New Drug $(IND)$ package for CLR 225, which is being developed for pancreatic cancer. The presentation also highlights the company's lead asset, iopofosine I 131, which achieved statistically significant response rates in a Phase 2b study for Waldenström macroglobulinemia and has received Breakthrough Therapy and PRIME designations in the US and EU, respectively. Plans are underway for regulatory submissions in both regions. Additional pipeline programs and expansion strategies, as well as the company's proprietary manufacturing and supply chain infrastructure, are also discussed. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.